Background: There is growing evidence showing the importance of fecal calprotectin assay in differentiating organic from functional colonic disorders. It is a simple, non-invasive technique than colonoscopy.Objectives: The aim of this study was to assess the value and sensitivity of fecal calprotectin (FCP) in patients with signs and symptoms suggestive of colonic disorders and to distinguish between organic and functional colonic pathology, to avoid unnecessary invasive techniques.Methods: A single stool sample was collected from each patient presenting with signs and symptoms suggestive of colonic disorders (abdominal pain, chronic diarrhea, weight loss, and anemia). Calprotectin concentration was measured by commercial ELIS System.Results: ESR results showed significant difference between organic non IBD group and all other studied groups. While, non significant difference was detected in between control, IBS and IBD groups. Comparison of fecal calprotectin results between all studied groups demonstrated no significant difference between control and IBS group, while a significant difference was noticed between IBS and IBD group and IBS and organic non IBD group. Conclusion: Fecal calprotectin has potential as a screening procedure to differentiate between patients with functional colonic disorders from other organic intestinal diseases as calprotectin concentration is rarely within the normal range in patients with IBD or colorectal cancer / adenomatous polyps.